FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2471032030> ?p ?o ?g. }

• W2471032030 endingPage "LBA2002" @default.
• W2471032030 startingPage "LBA2002" @default.
• W2471032030 abstract "LBA2002 Background: Despite treatment advances, survival of elderly GBM patients (pts) is usually < 12 months. Hypofractionated RT is advocated in order to shorten treatment time, and chemotherapy has been proposed as an alternative to RT. In a randomized trial we compared two different RT schedules with single-agent TMZ chemotherapy. Methods: Newly diagnosed GBM pts age ≥ 60 years with PS 0-2, were randomized to either standard RT (60 Gy in 2 Gy fractions over 6 weeks) or hypofractionated RT (34 Gy in 3,4 Gy fractions over 2 weeks) or 6 cycles of chemotherapy with TMZ (200 mg/m 2 day 1-5 every 28 days). Follow-up including quality of life, symptom checklist, and steroid dosing was completed at 6 weeks, 3 months, and 6 months after start of treatment. The primary study end point was overall survival (OS). Results: A total of 342 pts were included. 291 pts were randomized between the 3 treatment options, 51 pts between hypofractionated RT and TMZ. Median age was 70 years (range 60-88), 59% were male and 72% had undergone tumor resection, the remaining 28% had a diagnostic biopsy only. Performance status was 0-1 for 75% of pts. Survival data are available for 334 pts (98%), with 11 pts (3%) being alive. There was no significant difference in OS between the three treatment arms, with median survival being 8 months for TMZ, 7.5 months for hypofractionated RT and 6 months for 6 weeks RT (p=0.14). Conclusions: Elderly patients with GBM have a short survival. Time-consuming therapy that does not offer longer survival should therefore be avoided. Our study showed no advantage of standard 6 weeks RT compared to hypofractionated RT over 2 weeks or 6 cycles of TMZ chemotherapy. These results indicate that standard RT should no longer be offered to the elderly pt population with GBM. Exclusive TMZ chemotherapy may be an alternative to RT. Subgroup analyses and determination of molecular markers is ongoing. Whether outcome could be improved by concomitant chemoradiotherapy is subject of ongoing clinical trials. [Table: see text]" @default.
• W2471032030 created "2016-07-22" @default.
• W2471032030 creator A5001810357 @default.
• W2471032030 creator A5010791019 @default.
• W2471032030 creator A5013572301 @default.
• W2471032030 creator A5020314370 @default.
• W2471032030 creator A5026145582 @default.
• W2471032030 creator A5033870647 @default.
• W2471032030 creator A5053052330 @default.
• W2471032030 creator A5053746026 @default.
• W2471032030 creator A5084228112 @default.
• W2471032030 date "2010-06-20" @default.
• W2471032030 modified "2023-09-25" @default.
• W2471032030 title "Glioblastoma (GBM) in elderly patients: A randomized phase III trial comparing survival in patients treated with 6-week radiotherapy (RT) versus hypofractionated RT over 2 weeks versus temozolomide single-agent chemotherapy (TMZ)." @default.
• W2471032030 doi "https://doi.org/10.1200/jco.2010.28.18_suppl.lba2002" @default.
• W2471032030 hasPublicationYear "2010" @default.
• W2471032030 type Work @default.
• W2471032030 sameAs 2471032030 @default.
• W2471032030 citedByCount "36" @default.
• W2471032030 countsByYear W24710320302012 @default.
• W2471032030 countsByYear W24710320302013 @default.
• W2471032030 countsByYear W24710320302016 @default.
• W2471032030 countsByYear W24710320302019 @default.
• W2471032030 countsByYear W24710320302020 @default.
• W2471032030 crossrefType "journal-article" @default.
• W2471032030 hasAuthorship W2471032030A5001810357 @default.
• W2471032030 hasAuthorship W2471032030A5010791019 @default.
• W2471032030 hasAuthorship W2471032030A5013572301 @default.
• W2471032030 hasAuthorship W2471032030A5020314370 @default.
• W2471032030 hasAuthorship W2471032030A5026145582 @default.
• W2471032030 hasAuthorship W2471032030A5033870647 @default.
• W2471032030 hasAuthorship W2471032030A5053052330 @default.
• W2471032030 hasAuthorship W2471032030A5053746026 @default.
• W2471032030 hasAuthorship W2471032030A5084228112 @default.
• W2471032030 hasConcept C126322002 @default.
• W2471032030 hasConcept C141071460 @default.
• W2471032030 hasConcept C168563851 @default.
• W2471032030 hasConcept C203092338 @default.
• W2471032030 hasConcept C2776694085 @default.
• W2471032030 hasConcept C2777389519 @default.
• W2471032030 hasConcept C2780964509 @default.
• W2471032030 hasConcept C509974204 @default.
• W2471032030 hasConcept C71924100 @default.
• W2471032030 hasConceptScore W2471032030C126322002 @default.
• W2471032030 hasConceptScore W2471032030C141071460 @default.
• W2471032030 hasConceptScore W2471032030C168563851 @default.
• W2471032030 hasConceptScore W2471032030C203092338 @default.
• W2471032030 hasConceptScore W2471032030C2776694085 @default.
• W2471032030 hasConceptScore W2471032030C2777389519 @default.
• W2471032030 hasConceptScore W2471032030C2780964509 @default.
• W2471032030 hasConceptScore W2471032030C509974204 @default.
• W2471032030 hasConceptScore W2471032030C71924100 @default.
• W2471032030 hasIssue "18_suppl" @default.
• W2471032030 hasLocation W24710320301 @default.
• W2471032030 hasOpenAccess W2471032030 @default.
• W2471032030 hasPrimaryLocation W24710320301 @default.
• W2471032030 hasRelatedWork W163326248 @default.
• W2471032030 hasRelatedWork W1970674393 @default.
• W2471032030 hasRelatedWork W2128503410 @default.
• W2471032030 hasRelatedWork W2150741177 @default.
• W2471032030 hasRelatedWork W2154851015 @default.
• W2471032030 hasRelatedWork W2182919525 @default.
• W2471032030 hasRelatedWork W2324032012 @default.
• W2471032030 hasRelatedWork W2384322989 @default.
• W2471032030 hasRelatedWork W2390408846 @default.
• W2471032030 hasRelatedWork W4294682775 @default.
• W2471032030 hasVolume "28" @default.
• W2471032030 isParatext "false" @default.
• W2471032030 isRetracted "false" @default.
• W2471032030 magId "2471032030" @default.
• W2471032030 workType "article" @default.